Cetuximab in the treatment of colorectal cancer.
By R. Goldberg, A. Venook, R. Schilsky. Clinical advances in hematology & oncology : H&O, 2004
1,076 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/4e5c0355b006ec98e525bbc7c7bb8189f94c3815
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Tejpar
- W. De Roock
- E. Van Cutsem
- J. Chmielecki
- D. Jonker
- A. Sobrero
- H. Lenz
- C. Karapetis
Citations in the corpus
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “The antibody has been US Food and Drug Administration (FDA) approved for the treatment of colorectal and head and neck cancer”
- Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “In addition to the small-molecule kinase inhibitors, kinase-targeted antibodies have also demonstrated efficacy in various cancers, for example, cetuximab in colorectal and head and neck cancer, and trastuzumab in breast cancer [26, 27].”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, unknown): “(1) CPT-11 ? cetuximab [51], (2) Cetuximab/panitumumab monotherapy [52–55].”
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, methodology): “17 randomized phase 3 trial of cetuximab plus best supportive care vs best supportive care alone.(12) KRAS mutation analysis was performed by direct sequencing as described previously.”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “It has been shown that cetuximab improves the survival of chemorefractory patients compared with best supportive care (BSC) [I, B] [29, 30].”
- EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. (2008, background): “As the evaluation of cetuximab continues, with ongoing or recently-completed randomized trials in first-line (Cancer and Leukemia Group B 80203, Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer, and Cetuximab Combined with Irinotecan in First-Line Therapy for Metasta”